RA'ANANA, Israel, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has entered into a definitive agreement with YA II PN, Ltd. ("YA") for a registered direct offering of its ordinary shares, and has also entered into a Standby Equity Purchase Agreement ("SEPA") with YA providing additional equity financing flexibility.In ...

Hauppauge, NY, Dec. 11, 2025 (GLOBE NEWSWIRE) -- -- Cemtrex, Inc. (NASDAQ: CETX) (the “Company”), an advanced security technology and industrial services company, today announced that it has entered into a definitive agreement for the purchase of approximately 666,667 shares with a single institutional investor, at a purchase price of $3 per share, with gross proceeds to the Company expected to be $2 million to the Company. The transaction is expected to close on or about Dec 11, 2025, subject to the satisf ...

Core Points - Atlas Lithium Corporation has announced a registered direct offering of 2,500,000 shares of common stock at a price of $4.00 per share, resulting in gross proceeds of approximately $10 million [1][2] - The company plans to use the net proceeds from the offering for advancing its Neves Lithium Project towards production, as well as for working capital and general corporate purposes [1] - The offering is being conducted under an effective shelf registration statement declared effective by the SEC on September 3, 2025 [2] Financial Details - The offering price is set at $4.00 per share, with total gross proceeds expected to be around $10 million before deducting placement agent commissions and other expenses [1] - The closing of the offering is anticipated to occur on or about December 8, 2025, subject to customary closing conditions [1] Strategic Insights - The addition of two new long-term U.S. institutional investors is expected to strengthen the company's corporate profile and balance sheet [2] - A.G.P./Alliance Global Partners is acting as the sole placement agent for this offering [1]

ATHENS, Greece, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Imperial Petroleum Inc. (NASDAQ:IMPP) ("Imperial Petroleum" or the "Company"), a ship-owning company providing petroleum products, crude oil, and drybulk seaborne transportation services, today announced that it has entered into a securities purchase agreement with two institutional investors for the sale of 9,523,900 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) and accompanying Class F warrants to purchase up to 9,523,900 sh ...

Core Points - Lifezone Metals Limited has successfully closed its underwritten registered direct offering, raising approximately $15 million in gross proceeds [1] - The company plans to utilize the net proceeds for exploration of the Kabanga Nickel Project, project staffing, and other general corporate purposes [1]

Core Viewpoint - Univest Securities, LLC has successfully closed a registered direct offering of approximately $4.2 million for Boqii Holding Limited, a leading pet-focused platform in China [1][3]. Group 1: Offering Details - Boqii Holding Limited agreed to sell 1,500,000 Class A ordinary shares at a purchase price of $2.80 per share, or pre-funded warrants in lieu thereof [2]. - The total gross proceeds from the offering amounted to approximately $4.2 million [3]. - The offering was conducted under a shelf registration statement previously filed and declared effective by the SEC [4]. Group 2: Company Information - Boqii Holding Limited is recognized as a leading online destination for pet products in China, offering a wide range of high-quality products from global and local brands, as well as its own private labels [7]. - The company's online sales platforms, including Boqii Mall, provide customers with convenient access to pet products and an engaging shopping experience [7]. - Boqii also features a community platform for users to share knowledge and experiences related to pet care [7]. Group 3: Univest Securities Overview - Univest Securities, LLC has been registered with FINRA since 1994 and offers a variety of financial services, including investment banking and advisory [6]. - The firm has successfully raised over $1.7 billion in capital for issuers globally since 2019, completing approximately 100 transactions across various industries [6].

Core Viewpoint - Boqii Holding Ltd. has entered into a definitive agreement for a registered direct offering of 1,500,000 Class A ordinary shares at a price of $2.80 per share, expected to raise approximately $4.2 million in gross proceeds [1][2]. Group 1: Offering Details - The offering involves the sale of 1,500,000 Class A ordinary shares or pre-funded warrants at a purchase price of $2.80 per share [1]. - The transaction is anticipated to close on or about November 4, 2025, pending customary closing conditions [2]. - Univest Securities, LLC is acting as the sole placement agent for this offering [2]. Group 2: Regulatory Information - The offering is made pursuant to a shelf registration statement on Form F-3, which was declared effective by the SEC on November 23, 2022 [3]. - A final prospectus supplement and accompanying prospectus will be filed with the SEC and will be available on the SEC's website [3]. Group 3: Company Overview - Boqii Holding Ltd. is a leading pet-focused platform in China, offering a wide selection of pet products, including global and local brands as well as its private labels [5]. - The company operates online sales platforms such as Boqii Mall and provides an engaging shopping experience for customers [5]. - Boqii Community serves as an interactive content platform for pet lovers to share knowledge and experiences [5].

Core Points - Ekso Bionics Holdings, Inc. has entered into a definitive agreement for the purchase and sale of 769,490 shares of common stock at a price of $4.81 per share, expected to close around October 30, 2025 [1] - The gross proceeds from this offering are anticipated to be $3.7 million, which will be used for general corporate purposes including research and development, administrative costs, and working capital needs [3] - The shares are being offered under a "shelf" registration statement previously filed with the SEC, and the offering will be conducted via a prospectus [4] Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility for both medical and industrial applications [6] - The company focuses on improving health and quality of life through advanced robotics, and is recognized for its unique technologies that assist individuals with paralysis and enhance capabilities in various job sites [6] - Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol "EKSO" [6]

Core Points - T1 Energy Inc. has announced a registered direct offering of common stock, aiming to raise gross proceeds of $72 million [1][2] - The company will issue 22,153,850 shares at a price of $3.25 per share [2] - The offering is expected to close on or about October 24, 2025, subject to customary closing conditions [2] Financial Details - After the offering, T1 Energy will have approximately $155 million in cash, cash equivalents, and restricted cash, with $102 million being unrestricted [2] - The proceeds from the offering will be utilized for strategic investments, partnership development, and advancements in energy technology and infrastructure projects [8] Company Background - T1 Energy Inc. is focused on building an integrated U.S. supply chain for solar and batteries, having completed a transformative transaction in December 2024 [6] - The company is positioned as a leading solar manufacturing entity in the U.S. and is exploring value optimization opportunities in Europe [6]

Core Points - XORTX Therapeutics Inc. has entered into a securities purchase agreement for the sale of 1,746,631 common shares at a price of US$0.63 per share, aiming to raise gross proceeds of US$1.1 million [1][2] Group 1: Offering Details - The closing of the offering is expected on or about October 22, 2025, pending customary closing conditions and TSX Venture Exchange approval [2] - The net proceeds from the offering will be used for working capital and general corporate purposes [2] - D. Boral Capital LLC is acting as the sole placement agent for the offering [3] Group 2: Regulatory Information - The common shares will be issued under an effective shelf registration statement previously filed with the SEC [4] - A prospectus supplement detailing the terms of the offering will be filed with the SEC and will be available on their website [4] Group 3: Company Overview - XORTX is focused on developing therapies for gout and progressive kidney disease, with three clinically advanced products: XRx-026 for gout, XRx-008 for ADPKD, and XRx-101 for acute kidney injury [6] - The company is also developing XRx-225, a pre-clinical program for Type 2 diabetic nephropathy [6] - XORTX aims to improve the quality of life for individuals with gout and related diseases by targeting purine metabolism and xanthine oxidase to reduce uric acid production [6]